AUTL — Autolus Therapeutics Share News
0.000.00%
Last trade - 00:00- $428.49m
- $476.32m
- $75.39m
U.S. STOCKS ON THE MOVE-PayPal, Arm, New York Community Bancorp
Autolus climbs on collaboration with BioNTech to develop CAR-T cell therapies
Brief: BioNtech And Autolus Announce Strategic CAR-T Cell Therapy Collaboration To Advance Pipeline And Expand Late-Stage Programs
Brief: Biontech To Collaborate With Autolus In CAR-T Cell Therapy, Invests $200 Mln In Co
Brief: Autolus Therapeutics PLC Says FDA Is Not Currently Planning To Hold An Advisory Committee Meeting To Discuss Marketing Authorization Application
Brief: Autolus Therapeutics Announces The Appointment Of Robert W. Azelby To Its Board Of Directors
Brief: Autolus Therapeutics Announces Changes To Its Board Of Directors
US FDA investigating safety risk of CAR-T cancer therapies (updated)
CAR-T therapy developers fall amid U.S. FDA investigation
Brief: Autolus Therapeutics Submits Biologics License Application To U.S. Food And Drug Administration
Brief: Autolus Therapeutics Says Co Has Voluntarily Chosen To File Periodic And Current Reports On U.S. Domestic Issuer Forms
Autolus Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Autolus Therapeutics PLC expected to post a loss of 25 cents a share - Earnings Preview
Autolus Therapeutics PLC reports results for the quarter ended in June - Earnings Summary
Brief: Autolus Therapeutics plc posts Q2 net income USD -45.552 million
Autolus Therapeutics PLC expected to post a loss of 22 cents a share - Earnings Preview
Brief: Autolus Therapeutics Appoints Dr. Robert Iannone As A Non-Executive Director
U.S. STOCKS ON THE MOVE-Ford Motor, Theratechnologies, 3D Systems
Autolus Therapeutics rises as blood cancer therapy meets main goal in mid-stage study